Women and Lung Cancer Research and Preventive Services Act of 2025
- Bill Number
- H.R. 2319
- Origin Chamber
- House
- Congress
- 119th Congress, Session 2
- Policy Area
- Health
- Status
- Passed House
- Latest Action
- 2026-04-22: Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 380.
- Last Updated
- 2026-04-28T06:08:34Z
AI-Generated Summary
Purpose
The Women and Lung Cancer Research and Preventive Services Act of 2025 (H.R. 2319) directs the Secretary of Health and Human Services (HHS) to lead an interagency review of lung cancer research and related efforts, focusing on women and underserved populations. Underserved populations here refer to groups like low-income, rural, or minority communities eligible for lung cancer screening as recommended by the U.S. Preventive Services Task Force (USPSTF), an independent panel of experts. The goal is to identify ways to speed up research, improve access to preventive services (like screenings), and launch public awareness campaigns.
Key Provisions
- Interagency Review: HHS, consulting with the Departments of Defense (DoD) and Veterans Affairs (VA), must evaluate:
- Current research on lung cancer in women and underserved populations.
- Access to preventive services.
- Opportunities for public education campaigns.
- Review Content:
- Assess past research outcomes, ongoing activities, and knowledge gaps across federal agencies.
- Identify chances for collaborative, innovative research on:
- Environmental and genetic factors causing lung cancer in women.
- Better imaging tools for risk assessment, diagnosis, treatment, and combining with other preventive care.
- Develop a national strategy to expand lung cancer screening access, especially for women and underserved groups.
- Plan a national campaign to raise awareness about lung cancer in these groups and the need for early detection.
- Reporting Requirement: HHS must submit a comprehensive report to Congress within 2 years of the law's enactment.
Significant Changes to Existing Law
- Introduces a new mandate for an interagency review and report; does not amend prior laws but builds on existing USPSTF screening guidelines by pushing for expanded strategies and research focus.
- No direct funding or regulatory changes; it's primarily a study and planning directive.
Potential Impacts
- Government Agencies: HHS, DoD, and VA will allocate staff and resources for the review, potentially leading to coordinated future programs.
- Citizens: Women and underserved populations may benefit from accelerated research, wider screening access, and better education, potentially improving early detection rates and health outcomes for lung cancer (a leading cause of cancer deaths).
- International Relations: None apparent; focuses on domestic U.S. health research and services.
- Broader effects could include reduced health disparities if recommendations lead to new initiatives.
Main Stakeholders Affected
- Federal Agencies: HHS (lead), DoD, VA.
- Populations: Women and underserved groups eligible for USPSTF-recommended lung cancer screening.
- Others: Researchers, healthcare providers, public health organizations, lung cancer patients and advocates, Congress (receives report).
Notable Legal, Constitutional, or Political Implications
- Legal: Straightforward executive branch directive; enforceable via congressional oversight but no new enforcement mechanisms or penalties.
- Constitutional: Aligns with Congress's spending and commerce powers to promote public health; no apparent conflicts with individual rights.
- Political: Highlights health equity for women and underserved groups; could influence future funding or policies without partisan mandates.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Rep. Boyle, Brendan F. [D-PA-2]
Cosponsors (2)
Rep. Fitzpatrick, Brian K. [R-PA-1], Rep. Ciscomani, Juan [R-AZ-6]
Recent Actions
- 2026-04-22: Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 380.
- 2026-04-21: Motion to reconsider laid on the table Agreed to without objection.
- 2026-04-21: On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H3020)
- 2026-04-21: Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H3020)
- 2026-04-21: DEBATE - The House proceeded with forty minutes of debate on H.R. 2319.
- 2026-04-21: Considered under suspension of the rules. (consideration: CR H3020-3021)
- 2026-04-21: Mrs. Harshbarger moved to suspend the rules and pass the bill.
- 2025-11-18: Placed on the Union Calendar, Calendar No. 332.
- 2025-11-18: Reported by the Committee on Energy and Commerce. H. Rept. 119-382.
- 2025-11-18: Reported by the Committee on Energy and Commerce. H. Rept. 119-382.
- 2025-04-29: Ordered to be Reported by Voice Vote.
- 2025-04-29: Committee Consideration and Mark-up Session Held
- 2025-03-25: Referred to the House Committee on Energy and Commerce.
- 2025-03-25: Introduced in House
- 2025-03-25: Introduced in House
Bill Versions
- Women and Lung Cancer Research and Preventive Services Act of 2025 — issued 2026-04-21 — PDF (6 pages)
- Women and Lung Cancer Research and Preventive Services Act of 2025 — issued 2025-03-25 — PDF (4 pages)
- Women and Lung Cancer Research and Preventive Services Act of 2025 — issued 2026-04-22 — PDF (6 pages)
- Women and Lung Cancer Research and Preventive Services Act of 2025 — issued 2025-11-18 — PDF (6 pages)